Cidara Therapeutics Files 8-K Report

Cidara Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCidara Therapeutics, Inc.
Form Type8-K
Filed DateJun 23, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, financial-update

Related Tickers: CDTX

TL;DR

CDTX filed an 8-K on 6/23/25, check for updates.

AI Summary

On June 23, 2025, Cidara Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. No specific monetary transactions or new partnerships were detailed in the provided excerpt.

Why It Matters

This 8-K filing signals to investors and the market that Cidara Therapeutics has made a regulatory submission, potentially containing material updates about the company's operations or financial health.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific financial or operational disclosures that would indicate immediate risk.

Key Players & Entities

  • Cidara Therapeutics, Inc. (company) — Registrant
  • K2 Therapeutics, Inc. (company) — Former Company Name
  • June 23, 2025 (date) — Date of Report
  • 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 (address) — Principal Executive Offices
  • 858-752-6170 (phone_number) — Principal Executive Offices Phone Number

FAQ

What is the primary purpose of this 8-K filing for Cidara Therapeutics?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences.

When was this 8-K report filed?

The report was filed on June 23, 2025.

What was Cidara Therapeutics' former company name?

Cidara Therapeutics, Inc. was formerly known as K2 Therapeutics, Inc.

Where are Cidara Therapeutics' principal executive offices located?

The principal executive offices are located at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121.

What is the telephone number for Cidara Therapeutics' principal executive offices?

The telephone number is (858) 752-6170.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Cidara Therapeutics, Inc..

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.